Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
host | mouse |
isotype | IgG |
clonality | monoclonal |
concentration | concentrate, predilute |
applications | IHC |
reactivity | human |
available size | 0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted |
rabbit anti-PRAME monoclonal antibody (ZR383) 6345
$160.00 – $528.00
Antibody summary
- Rabbit monoclonal to PRAME
- Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
- Reacts with: Human
- Isotype:IgG
- Control: Testis or melanoma
- Visualization: Nucleus, cytoplasm, cell surface, chromosome, Golgi apparatus.
- 0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted
rabbit anti-PRAME monoclonal antibody ZR383 6345
target relevance |
---|
Protein names Melanoma antigen preferentially expressed in tumors (Opa-interacting protein 4) (OIP-4) (Preferentially expressed antigen of melanoma) |
Protein family PRAME family |
Mass 57890Da |
Function Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:21822215, PubMed:26138980). The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980). In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation (PubMed:21822215). Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis (PubMed:16179254). . |
Pathway PATHWAY: Protein modification; protein ubiquitination. . |
Subellular location Nucleus . Chromosome . Cytoplasm . Golgi apparatus . Cell membrane . Note=Associates with chromatin; specifically enriched at transcriptionally active promoters that are also bound by nuclear transcription factor Y (composed of NFYA, NFYB and NFYC) and at enhancers (PubMed:21822215). Recruited to the Golgi apparatus in response to interferon gamma (IFNG) treatment (PubMed:23460923). . |
Tissues Expressed in testis. Detected in samples of kidney, brain and skin. . |
Structure Component of a CRL2 E3 ubiquitin-protein ligase complex, also named ECS (Elongin BC-CUL2/5-SOCS-box protein) complex, composed of CUL2, Elongin BC (ELOB and ELOC), RBX1 and substrate-specific adapter PRAME (PubMed:21822215, PubMed:23460923, PubMed:26138980). Interacts with RARA (via the ligand-binding domain); the interaction is direct and ligand (retinoic acid)-dependent (PubMed:16179254). Interacts with EZH2; required to repress RAR signaling (PubMed:16179254). . |
Target Relevance information above includes information from UniProt accession: P78395 |
The UniProt Consortium |
Data
Formalin-fixed, paraffin-embedded human liver with metastatic melanoma stained with anti-PRAME antibody using peroxidase-conjugate and DAB chromogen. Note the nuclear staining in tumor cells |
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.pmid | title | authors | citation |
---|
Protocols
relevant to this product |
---|
IHC |
Documents
# | |||
---|---|---|---|
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information. |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.